Yahoo · Oct 27, 2026
Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 Earnings
Lilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges.
GP
NASDAQ · GPCR
Structure Therapeutics Inc.
Healthcare · Biotechnology
$21.87
Down-$0.07 (-0.32%)
Updated Nov 2, 2026, 3:10 AM
SID Score
3.6/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 3.88B
- P/E ratio
- -7.22
- Dividend yield
- 0.00%
- 52-week range
- $20.50 – $94.90
- Volume
- 696.98K
- Avg. volume
- 1.4M
Price performance · GPCR
GPCR price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
GPCR closed at $21.87 after 20 trading sessions, down 20.73% for the selected period.
- Last close
- $21.87
- Period change
- -20.73%
- Period low
- $21.08
- Period high
- $27.59
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $21.59 | $22.36 | $21.07 | $21.87 | 696.98K |
| Oct 29, 2026 | $21.51 | $22.1644 | $21.39 | $21.94 | 929.52K |
| Oct 28, 2026 | $21.29 | $21.6654 | $20.50 | $21.48 | 987.48K |
| Oct 27, 2026 | $21.15 | $22.08 | $20.90 | $21.55 | 731.61K |
| Oct 26, 2026 | $21.16 | $21.98 | $21.05 | $21.10 | 688.97K |
| Oct 23, 2026 | $21.79 | $21.97 | $21.13 | $21.19 | 798.11K |
| Oct 22, 2026 | $21.72 | $22.5483 | $21.72 | $21.93 | 702.38K |
| Oct 21, 2026 | $23.00 | $23.32 | $21.77 | $22.01 | 804.46K |
| Oct 20, 2026 | $22.11 | $23.83 | $22.11 | $22.88 | 1.41M |
| Oct 19, 2026 | $21.08 | $22.2499 | $20.7401 | $22.01 | 1.31M |
| Oct 16, 2026 | $22.15 | $22.205 | $20.725 | $21.08 | 1.16M |
| Oct 15, 2026 | $21.89 | $22.615 | $21.81 | $22.19 | 1.41M |
| Oct 14, 2026 | $22.46 | $22.89 | $21.55 | $21.88 | 2.07M |
| Oct 13, 2026 | $23.92 | $24.03 | $22.10 | $22.31 | 1.45M |
| Oct 12, 2026 | $25.25 | $25.50 | $23.89 | $23.91 | 1.66M |
| Oct 9, 2026 | $25.73 | $26.15 | $25.29 | $25.54 | 593.23K |
| Oct 8, 2026 | $26.57 | $26.80 | $25.09 | $25.67 | 939.74K |
| Oct 7, 2026 | $27.14 | $28.05 | $26.38 | $26.68 | 1.05M |
| Oct 6, 2026 | $27.55 | $27.8457 | $26.69 | $27.47 | 1.42M |
| Oct 5, 2026 | $28.10 | $28.205 | $26.41 | $27.59 | 1.87M |
Latest GPCR news
The latest Smart Investors Daily articles mentioning GPCR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GPCR research
Overview
Company profile and research snapshot.
Company profile
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $91.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | Citigroup | Buy | — |
| Aug 7, 2026 | Citizens | Market Outperform | — |
| Jun 11, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 21, 2026
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
Yahoo · Oct 19, 2026
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD. Title: Aleniglipron in Participants Living with Overweight or Obesi
Yahoo · Oct 19, 2026
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
